CCCC — C4 Therapeutics Share News
0.000.00%
Last trade - 00:00- $391.22m
- $137.56m
- $35.95m
Brief: C4 Therapeutics Files For Mixed Shelf Of Up To $400 Mln
Brief: C4 Therapeutics Reports Third Quarter 2024 Financial Results
Brief: C4 Therapeutics Q3 EPS USD -0.35 Vs. IBES Estimate USD -0.38
Brief: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
C4 Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: C4 Therapeutics Says CFT1946 Well-Tolerated At All Dose Levels No Dose-Limiting Toxicities
C4 Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: C4 Therapeutics Q2 EPS USD -0.26 Vs. IBES Estimate USD -0.37
C4 Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: C4 Therapeutics Q1 EPS USD -0.41 Vs. IBES Estimate USD -0.35
Brief: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
C4 Therapeutics rises on license agreement with Merck KGaA
Brief: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
C4 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview